Werewolf Therapeutics to present WTX-124 Phase 1/1b cancer study at SITC 2026
HOWL•Werewolf Therapeutics will present studies of WTX-124 and WTX-330 at the Society for Immunotherapy of Cancer meeting in Phoenix on November 4-8, 2026. A November 7 oral presentation will cover WTX-124 alone or with pembrolizumab in advanced solid tumors; a poster will feature WTX-330 testing in relapsed or refractory solid tumors.
1. SITC presentations
Werewolf Therapeutics will present cancer studies at the Society for Immunotherapy of Cancer meeting, scheduled for November 4-8, 2026, in Phoenix. On November 7, an oral presentation will cover Phase 1/1b testing of WTX-124 alone or with pembrolizumab in advanced solid tumors, while a poster will feature the Phase 1b/2 study of WTX-330 in patients with relapsed or refractory solid tumors. Both experimental treatments are designed to activate selectively within tumors to stimulate immune responses against cancer.
